• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Study: Asthma Patients Maintain High Medication Adherence Using Propeller Health’s Platform

by Fred Pennic 11/19/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Propeller Health’s Platform

What You Should Know:

– New study out from Propeller and Chicago’s NorthShore University HealthSystem shows that asthma patients maintain higher medication adherence and decrease their rescue inhaler use when using a digital health platform.

– The study looked at 100 patients recruited from NorthShore practices, half of whom used Propeller to manage their condition and half of whom did not.

– The treatment group maintained their high medication adherence at 68%, while the control group experienced a 17% decline in adherence over the course of the study. The treatment group also increased days without needing their rescue inhaler by 19%, 13% more than in the control group.


Patients using Propeller Health’s digital health platform to manage their asthma experienced a significant decline in rescue inhaler use and higher medication adherence rates compared to patients not using the platform, according to a new randomized controlled trial published in The Journal of Allergy and Clinical Immunology: In Practice by researchers from Propeller and NorthShore University HealthSystem. The study reveals maintained their high medication adherence at 68%, while the control group experienced a 17% decline in adherence over the course of the study

Poor adherence to asthma medication and overuse of rescue inhalers have both been associated with increased asthma morbidity in previous research. Studies reveal that patients often overestimate their level of adherence to their clinician, leading to costly treatments that may not be appropriate or necessary to curb symptoms.

Randomized Clinical Trial Details

The published study features a randomized controlled trial that enrolled 100 patients with uncontrolled asthma, 25 to 65 years of age. Patients were recruited between April 2018 and 2019 from allergist and pulmonologist practices at NorthShore University HealthSystem in Chicago. Treatment and control group participants were both attached a small sensor to their controller and rescue inhalers. The treatment group received insights on their medication use in the Propeller app, including reminders to take missed or late doses and reports on their usage and possible triggers.

Utilizing Propeller’s digital health platform, clinicians had had access to the treatment patients’ controller and rescue medication data. If patient utilization indicated poor adherence or worsening control, patients were contacted to address adherence and review asthma control status. The control group’s medication use was remotely monitored, but they did not receive insights in the app or outreach from providers.

Clinical Trial Outcomes/Results

The study’s treatment group maintained its high medication adherence at 68%, while the control group experienced a 17% decline in adherence over the course of the study. In addition, Propeller users’ days without needing their rescue inhaler increased 19% in the treatment group, 13% more than in the control group.

“Increasing adherence and reducing rescue use are critical to improving the health and well-being of asthma patients,” said Giselle Monsaim, MD, lead author of the study and attending physician in the Departments of Medicine, Division of Pulmonary, Critical Care, Allergy and Immunology at NorthShore University HealthSystem. “We’re pleased to add to the body of research that shows digital health can play an important role in maintaining high adherence rates and increasing days without symptoms for people with asthma.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Asthma, asthma health app, Clinical Trial, Clinical Trials, digital health, MD, medication, Medication Adherence, Propeller Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |